Therapy Areas: Inflammatory Diseases
Halia Therapeutics doses first participant in Phase 1 clinical study with HT-6184
17 June 2022 -

Halia Therapeutics, a US-based clinical-stage biotechnology company, announced on Wednesday that it has dosed its first participant in a Phase 1 clinical study with HT-6184, a novel small molecule inhibitor of NEK7 and the NLRP3 pathway.

HT-6184 is the lead molecule from the company's structure-based drug design strategy that has developed a range of novel drug candidates aimed at essential mediators of inflammation with the potential to treat various diseases, including heart disease, Alzheimer's and Parkinson's disease, many cancers, fatty liver diseases, inflammatory bowel disorders, and other conditions linked to chronic inflammation.

The Phase 1 trial, a single-centre, randomised, placebo-controlled, single ascending dose study, is intended to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HT-6184 in up to 32 healthy human subjects.

Login
Username:

Password: